Editors Overview

tdd maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Open Access
Special Issue
Topic

Characterization and Biomedical Application Opportunities of the Nanoparticle’s Protein of Omicron

Abstract Submission Deadline : November 30, 2024

Manuscript Submission Deadline : December 25, 2024

Special Issue Description

By observing the surface plasmon resonance (SPR) band shift of gold nanoparticles with some diameters, the adsorption of the SARS-CoV-2 Omicron spike protein to the nano-gold colloid surfaces was investigated. The reversible creation of the gold colloid aggregates was triggered by the externally altered pH between 3 and 11 at 24.5 0.4 °C. The formation/deformation of the aggregates was observed as a red/blue shift in the peak of the SPR band. For the gold colloids with d = 10, 15, and 20 nm, there was no evidence of reversible aggregation. The coronavirus, or SARS-CoV-2, has experienced spontaneous mutation and antigenic variation throughout time and numerous extremely alarming forms, including the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) coronaviruses, have been described. The spike protein has 32 mutations in the Omicron variation (B.1.1.529), which significantly increased its pathogenicity when compared to earlier variants. Omicron has a 5.5–11 times greater mutation rate in the receptor-binding motif (RBM) than Alpha, Beta, and Delta SARS-CoV-2 variants. The receptor binding domain (RBD) of the S1 subunit spike protein is made up of 319–541 acids. G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, and Y505H are the reported mutations for Omicron in the RBD region.

Keywords

Nanoparticles, Omicron, Protein folding, Aggregation, Surface plasmon resonance

Manuscript Submission information

Manuscripts should be submitted online via the manuscript Engine. Once you register on APID, click here to go to the submission form. Manuscripts can be submitted until the deadline.
All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a Double-blind peer-review process. A guide for authors and other relevant information for the submission of manuscripts is available on the Instructions for Authors page.

Participating journals:


2394-7268

Journal Name

Trends in Drug Delivery

Abbrivation


tdd

ISSN


2394-7268

Since

2014

APC

950  $